Bio-Rad Laboratories, Inc.
Market Cap
$7.27B
P/E Ratio
9.68
EPS
$27.85
Dividend Yield
0.00%
52-Week Range
$211.43 — $343.12
Volume
216.24K
Avg Volume
257.85K
Beta
1.20
P/E (TTM)
9.68
Forward P/E
26.18
PEG Ratio
0.04
P/S (TTM)
2.82
P/B (TTM)
0.98
P/FCF
84.63
EV/EBITDA
-22.22x
EV/Sales
—
ROE (TTM)
0.11%
ROA (TTM)
0.07%
ROIC
0.01%
Gross Margin
0.52%
Operating Margin
0.09%
Net Margin
-0.52%
Debt/Equity
0.21
Current Ratio
5.62
EPS Growth (YoY)
-1.54%
Revenue Growth (YoY)
+0.04%
EPS Growth (3Y)
+0.08%
EPS Growth (5Y)
-0.30%
Sales Growth (3Y)
-0.03%
Sales Growth (5Y)
+0.01%
EPS Est (This Year)
$10.29
EPS Est (Next Year)
$11.55
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$57.19
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $327.50(21.5% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
26.99M
Float
18.09M
Free Float %
67.03%
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
NYSE
IPO Date
1980-02-27
Employees
7700
CEO
Norman D. Schwartz
Index Membership
—
Website
https://www.bio-rad.com
Bio-Rad Laboratories, Inc. (BIO) is a healthcare company in the medical - devices industry listed on the NYSE. With a market capitalization of $7.27B, a P/E ratio of 9.68, BIO is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare BIO against other stocks using dozens of fundamental and technical filters.
Bio-Rad Laboratories, Inc. (BIO) has a trailing twelve-month (TTM) P/E ratio of 9.68. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Bio-Rad Laboratories, Inc. (BIO) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Bio-Rad Laboratories, Inc. (BIO) has a market capitalization of $7.27 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Bio-Rad Laboratories, Inc. (BIO) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $327.50 implies 21.5% upside from the current price.